Skip Ribbon Commands
Skip to main content
Sign In
{{'GLOBAL_MESSAGE_OR' | translate}}
{{'ELOQUA_BANNER_ACCEPT' | translate}}
{{'ELOQUA_BANNER_DECLINE' | translate}}
Gene Therapy:
Virus Factories of the Future

Research has shown that the Quantum® Cell Expansion System is capable of producing high-titer retroviruses, including lentivirus, at titers comparable to those of flask-based processes (2 × 108 particles), with a dramatic reduction in labor and a substantial increase in yield.1

Current studies are also exploring the feasibility of producing adeno-associated virus (AAV8, AAV9). The Quantum system's ability to automate the manual cell culture process makes it a powerful tool for carrying out plasmid transfections and viral transductions in a functionally closed system while aiding in the current good manufacturing practice (cGMP) compliance of the manufacturing process.

From preclinical application to clinical trials or commercialization, whether your company is a startup or an industry leader, we look forward to supporting your process and helping you prepare for the road ahead.

Read about viral production at Eufets GmBH

Download the scientific poster: Exploring Good Manufacturing Practice (GMP) Production of Lentiviral Vectors

1Sheu J, et al., "Large-Scale Production of Clinical Grade Lentiviral Vector for Induced Pluripotent Stem Cell Induction in a Hollow-Fiber Bioreactor." 2014 ASGCT 17th Annual Meeting. Washington D.C., USA. 23 May 2014. Poster [728].

Customers are responsible for validating the use of the Quantum system to expand cells for their intended therapy.


{{'SEARCH_MODAL_TITLE' | translate }}
{{'SEARCH_MODAL_OR' | translate }}

{{'SEARCH_MODAL_BROWSE' | translate }}
{{$index+1}}. {{s.label}}